Prosztatarák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

80+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 202 125 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Törökország· EU contribution 398 612 EUR· until 2029. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.

5 of 32 running projects, newest first. Listed amounts together: 116,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

  NCT06298838· IRCCS San Raffaele· Frissítve: 2026. nov. 6.

  “Difficulties in patient recruitment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Peter MacCallum Cancer Centre, Australia· Frissítve: 2026. okt. 30.

  “Funding issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

  NCT05960578· University of Washington· Frissítve: 2026. okt. 19.

  “The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

  NCT06982222· National Cancer Institute (NCI)· Frissítve: 2026. aug. 28.

  “Other - Protocol moved to Withdrawn”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

  NCT06200103· Mayo Clinic· Frissítve: 2026. aug. 20.

  “Pending additional funding.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

  NCT05995236· Methodist Health System· Frissítve: 2026. aug. 4.

  “So far, we have not been able to collect meaningful data for these patients which also led to our decision to close this study before attempting write up and publish any results”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

  NCT04461509· Alessandro D'Agnolo· Frissítve: 2026. júl. 22.

  “Funding ceased before all specimen collection and analysis could be completed”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

  NCT05422105· Primo Biotechnology Co., Ltd· Frissítve: 2026. júl. 6.

  “Interim Analysis”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

  NCT04745871· University Hospital, Brest· Frissítve: 2026. jún. 11.

  “In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today, PSMA PET/CT has become routine and is performed before MTB review.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

  NCT04716725· Thomas Hope· Frissítve: 2026. máj. 15.

  “Low accrual”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

  NCT06894511· Novartis Pharmaceuticals· Forrás

• Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

  NCT07914855· National Cancer Institute (NCI)· Forrás

• A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

  2024-512340-32-01· Novartis Pharma AG· Forrás

• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT04221542· Amgen· Forrás

• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

  NCT06004661· Novartis Pharmaceuticals· Forrás

• 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Novartis Pharmaceuticals· Forrás

• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Novartis Pharmaceuticals· Forrás

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Forrás

• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  NCT06095089· Janssen Research & Development, LLC· Forrás

• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Janssen Research & Development, LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 153
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 464
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 61

• Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.

  BMC Genom Data, 2026. máj.

• Costs and benefits of whole-exome, whole-transcriptome sequencing versus 50-gene panels for genomic profiling in solid tumors.

  J Med Econ, 2026. márc.

• Exome sequencing points to pathogenic ATM variants in gastric cancer.

  Eur J Hum Genet, 2025. dec.

• Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening.

  Ann Med, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.